Related references
Note: Only part of the references are listed.Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia
K. A. Rogers et al.
LEUKEMIA (2016)
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome
Preetesh Jain et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions
Ciara L. Freeman et al.
BLOOD (2015)
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
Samantha M. Jaglowski et al.
BLOOD (2015)
Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial
Jennifer R. Brown et al.
BLOOD (2015)
Familial predisposition and genetic risk factors for lymphoma
James R. Cerhan et al.
BLOOD (2015)
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia
Zachary A. Hing et al.
BLOOD (2015)
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia
Jennifer R. Brown et al.
BLOOD (2015)
Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8
Maria Gounari et al.
BLOOD (2015)
A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
Susan M. O'Brien et al.
BLOOD (2015)
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
Ta-Ming Liu et al.
BLOOD (2015)
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib
Clare Sun et al.
BLOOD (2015)
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Preetesh Jain et al.
BLOOD (2015)
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression
Petra Langerbeins et al.
FUTURE ONCOLOGY (2015)
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients
Alessandra Tedeschi et al.
HAEMATOLOGICA (2015)
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
Andrew H. Lipsky et al.
HAEMATOLOGICA (2015)
Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia
Larry Mansouri et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
Peter Hillmen et al.
LANCET (2015)
Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway
Marwan Kwok et al.
LANCET (2015)
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study
Marinus H. J. van Oers et al.
LANCET ONCOLOGY (2015)
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
Mohammed Z. H. Farooqui et al.
LANCET ONCOLOGY (2015)
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
V. Goede et al.
LEUKEMIA (2015)
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente et al.
NATURE (2015)
Mutations driving CLL and their evolution in progression and relapse
Dan A. Landau et al.
NATURE (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?
Maria Chaudhry et al.
EXPERT REVIEW OF HEMATOLOGY (2015)
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients
Alessandra Tedeschi et al.
HAEMATOLOGICA (2015)
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
Andrew H. Lipsky et al.
HAEMATOLOGICA (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations
Panagiotis Baliakas et al.
BLOOD (2015)
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
S. Kamel et al.
LEUKEMIA (2015)
Recurrent mutations refine prognosis in chronic lymphocytic leukemia
P. Baliakas et al.
LEUKEMIA (2015)
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes
Ohad Benjamini et al.
LEUKEMIA & LYMPHOMA (2015)
Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
Luciano J. Costa et al.
LEUKEMIA & LYMPHOMA (2015)
Single-Cell Analysis and Next-Generation Immuno-Sequencing Show That Multiple Clones Persist in Patients with Chronic Lymphocytic Leukemia
Jitra Kriangkum et al.
PLOS ONE (2015)
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)
Constantine S. Tam et al.
BLOOD (2014)
How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
Arnon P. Kater et al.
BLOOD (2014)
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Stephan Stilgenbauer et al.
BLOOD (2014)
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study
Guillaume Cartron et al.
BLOOD (2014)
Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness
Monica Messina et al.
BLOOD (2014)
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
Julie R. McMullen et al.
BLOOD (2014)
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
Natali Pflug et al.
BLOOD (2014)
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2014)
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
Jennifer A. Woyach et al.
BLOOD (2014)
Long-term follow-up of a phase 2 trial of single agent lenalidomidein previously untreated patients with chronic lymphocytic leukaemia
Christine I. Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
New Strategies in Chronic Lymphocytic Leukemia: Shifting Treatment Paradigms
Farrukh T. Awan et al.
CLINICAL CANCER RESEARCH (2014)
ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial
Matthew J. J. Rose-Zerilli et al.
HAEMATOLOGICA (2014)
Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium
Danelle F. James et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
Susan O'Brien et al.
LANCET ONCOLOGY (2014)
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
Jan A. Burger et al.
LANCET ONCOLOGY (2014)
Chronic Lymphocytic Leukemia Cells in a Lymph Node Microenvironment Depict Molecular Signature Associated with an Aggressive Disease
Amit K. Mittal et al.
MOLECULAR MEDICINE (2014)
Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion
M. Le Garff-Tavernier et al.
LEUKEMIA (2014)
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients
S. Jeromin et al.
LEUKEMIA (2014)
Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells
Y. Zhong et al.
LEUKEMIA (2014)
NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment
Sabina Chiaretti et al.
LEUKEMIA & LYMPHOMA (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Richter's syndrome - update on biology and management
Preetesh Jain et al.
EXPERT OPINION ON ORPHAN DRUGS (2014)
Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks et al.
NATURE REVIEWS CANCER (2014)
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2013)
Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
Betty Y. Chang et al.
BLOOD (2013)
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2013)
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
Dan A. Landau et al.
CELL (2013)
Biology of Chronic Lymphocytic Leukemia in Different Microenvironments Clinical and Therapeutic Implications
Yair Herishanu et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2013)
Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Xavier C. Badoux et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients
S. Weissmann et al.
LEUKEMIA (2013)
The evolutionary biography of chronic lymphocytic leukemia
Xose S. Puente et al.
NATURE GENETICS (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells
Stefania Fiorcari et al.
PLOS ONE (2013)
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2012)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia
Kenneth A. Foon et al.
BLOOD (2012)
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2012)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial
Wolfgang U. Knauf et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Molecular pathogenesis of chronic lymphocytic leukemia
Gianluca Gaidano et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
Sebastian Boettcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia
Victor Quesada et al.
NATURE GENETICS (2012)
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2011)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia
William G. Wierda et al.
BLOOD (2011)
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia
Sameer A. Parikh et al.
BLOOD (2011)
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel et al.
BLOOD (2011)
B-cell receptor signaling in chronic lymphocytic leukemia
Freda K. Stevenson et al.
BLOOD (2011)
Advances in the Clinical Staging of Chronic Lymphocytic Leukemia
Kanti R. Rai et al.
CLINICAL CHEMISTRY (2011)
Fludarabine Versus Chlorambucil: Is the Debate Over?
Kanti R. Rai et al.
Clinical Lymphoma Myeloma & Leukemia (2011)
Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712
Jennifer A. Woyach et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente et al.
NATURE (2011)
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Lili Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
Sarah E. M. Herman et al.
BLOOD (2010)
Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study)
Tadeusz Robak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
Thorsten Zenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation
Jan A. Burger et al.
BLOOD (2009)
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience
Constantine S. Tam et al.
BLOOD (2009)
Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses
Nicole Lamanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
Peter Hillmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion
Belinda Austen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Neil E. Kay et al.
BLOOD (2007)
The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease
P. G. Longo et al.
LEUKEMIA (2007)
Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations
Kostas Stamatopoulos et al.
BLOOD (2007)
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
Zhengying Pan et al.
CHEMMEDCHEM (2007)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mechanisms of disease: Chronic lymphocytic leukemia
N Chiorazzi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia
BT Messmer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Clinical staging and prognostic markers in chronic lymphocytic leukemia
KR Rai et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2004)
Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vλ2-14 gene use and homologous CDR3s:: implicating recognition of a common antigen epitope
G Tobin et al.
BLOOD (2003)
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the, cytotoxic activity of either drug alone
N Di Gaetano et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Rituximab dose-escalation trial in chronic lymphocytic leukemia
SM O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
